Capital International Ltd. CA Has $2.58 Million Stock Position in Corteva, Inc. (NYSE:CTVA)

Capital International Ltd. CA cut its stake in shares of Corteva, Inc. (NYSE:CTVA) by 25.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 44,658 shares of the company’s stock after selling 15,277 shares during the period. Capital International Ltd. CA’s holdings in Corteva were worth $2,575,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. &PARTNERS increased its position in Corteva by 4.3% during the first quarter. &PARTNERS now owns 4,829 shares of the company’s stock worth $278,000 after acquiring an additional 200 shares during the period. Herr Investment Group LLC raised its position in shares of Corteva by 2.8% in the first quarter. Herr Investment Group LLC now owns 7,400 shares of the company’s stock valued at $427,000 after buying an additional 200 shares in the last quarter. Baxter Bros Inc. boosted its stake in shares of Corteva by 1.2% in the fourth quarter. Baxter Bros Inc. now owns 17,576 shares of the company’s stock valued at $842,000 after buying an additional 215 shares during the period. Albion Financial Group UT boosted its stake in shares of Corteva by 77.2% in the first quarter. Albion Financial Group UT now owns 505 shares of the company’s stock valued at $29,000 after buying an additional 220 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Corteva by 1.3% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 17,986 shares of the company’s stock worth $1,037,000 after acquiring an additional 227 shares during the period. Institutional investors own 81.54% of the company’s stock.

Insider Transactions at Corteva

In other news, SVP Cornel B. Fuerer sold 39,736 shares of Corteva stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $57.41, for a total value of $2,281,243.76. Following the completion of the transaction, the senior vice president now directly owns 126,628 shares of the company’s stock, valued at approximately $7,269,713.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, insider Brian Titus sold 12,134 shares of the stock in a transaction on Monday, May 6th. The shares were sold at an average price of $56.65, for a total transaction of $687,391.10. Following the transaction, the insider now directly owns 13,495 shares of the company’s stock, valued at $764,491.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Cornel B. Fuerer sold 39,736 shares of Corteva stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $57.41, for a total transaction of $2,281,243.76. Following the completion of the sale, the senior vice president now directly owns 126,628 shares of the company’s stock, valued at $7,269,713.48. The disclosure for this sale can be found here. Insiders sold a total of 83,556 shares of company stock worth $4,795,016 over the last three months. 0.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their price objective on Corteva from $66.00 to $67.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Oppenheimer raised their target price on shares of Corteva from $67.00 to $69.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Barclays upped their price target on shares of Corteva from $55.00 to $58.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 10th. Mizuho decreased their price objective on shares of Corteva from $61.00 to $60.00 and set a “buy” rating on the stock in a research note on Tuesday, June 18th. Finally, Canaccord Genuity Group boosted their price objective on shares of Corteva from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $63.00.

Corteva Trading Up 0.2 %

NYSE CTVA traded up $0.11 on Friday, hitting $55.39. The company’s stock had a trading volume of 2,237,847 shares, compared to its average volume of 3,425,469. The company’s 50-day moving average is $53.68 and its 200 day moving average is $53.58. The firm has a market cap of $38.61 billion, a PE ratio of 70.11, a PEG ratio of 1.45 and a beta of 0.77. Corteva, Inc. has a 1-year low of $43.22 and a 1-year high of $58.76. The company has a quick ratio of 0.97, a current ratio of 1.51 and a debt-to-equity ratio of 0.10.

Corteva (NYSE:CTVA) last announced its earnings results on Wednesday, May 1st. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.79 by $0.10. The firm had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $4.65 billion. Corteva had a return on equity of 6.68% and a net margin of 3.32%. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.16 EPS. As a group, analysts predict that Corteva, Inc. will post 2.78 earnings per share for the current fiscal year.

Corteva Profile

Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.